Skip to main content
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. — Investor Relations & Filings

Ticker · OVID ISIN · US6904691010 LEI · 549300H36NUI4L6U8F17 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2026-06-03 Board/Management Inform…
Country US United States of America
Listing US OVID

About Ovid Therapeutics Inc.

https://ovidrx.com/

Ovid Therapeutics Inc. is a biopharmaceutical company that develops targeted small molecule therapies for neurological conditions. The company's primary focus is on conquering epilepsies and other brain disorders by creating treatments that aim to reduce seizures and offer improved safety and tolerability. Ovid's scientific approach involves pioneering compounds with unique or potentially best-in-class mechanisms of action to address significant unmet medical needs. The company's mission is to develop medicines that improve the lives of patients and families affected by these conditions.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 98% confidence The document is a Form 8-K (Current Report) from Ovid Therapeutics that discloses Item 5.02: the appointment of a new director, increase in board size, and related director compensation arrangements. This clearly constitutes an announcement of changes in the company’s board of directors and senior management. Such filings are classified under Board/Management Information (MANG).
2026-06-03 English
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
Report Publication Announcement Classification · 84% confidence The document is a short (3,601-character) SEC Form 8-K that states a press release containing first quarter 2026 financial results was issued and is furnished as Exhibit 99.1. It does not include detailed financial statements itself but announces the report is attached. Per the “menu vs. meal” rule, this is a report publication announcement, not the report itself.
2026-05-12 English
ARS - Ovid Therapeutics Inc. (0001636651) (Filer)
Annual Report
2026-04-27 English
DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
424B3 - Ovid Therapeutics Inc. (0001636651) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to a registration statement on Form S-3. It details the resale of shares of common stock by selling stockholders following a private placement. The document includes information about the offering, risk factors, use of proceeds, plan of distribution, and other related disclosures. It is not a financial report, earnings release, or management discussion but rather a disclosure document related to securities registration and resale. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital structure changes through the private placement and resale registration.
2026-04-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.